表纸
市场调查报告书

人工呼吸器相关肺炎(VAP): 开发平台分析

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 264097
出版日期 内容资讯 英文 147 Pages
订单完成后即时交付
价格
Back to Top
人工呼吸器相关肺炎(VAP): 开发平台分析 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 147 Pages
简介

呼吸器相关肺炎(VAP)是气管插管或气管切开戴上人工呼吸器后,48小时内发病的肺炎,原因是细菌入侵下气管及肺所造成的。最重要的症状为发烧、体温低、脓性痰、低氧血等。

本报告提供人工呼吸器相关肺炎(VAP)的治疗药开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等相关的系统性资讯。

目录

简介

人工呼吸器相关肺炎(VAP)概要

治疗药的开发

  • 开发中产品:概要
  • 开发中产品:比较分析

开发中的治疗药:各企业

调查中的治疗药:大学/研究机关别

开发中产品的概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品
  • 开发阶段不明的产品

开发中的产品:各企业

调查中的产品:大学/研究机关别

开发治疗药的企业

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • MedImmune, LLC
  • Meiji Seikafaruma
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Tetraphase Pharmaceuticals Inc.

治疗药的评估

  • 单独疗法的产品
  • 联合治疗的产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • (amikacin + fosfomycin)
  • (avibactam + ceftazidime)
  • (ceftolozane sulfate + tazobactam sodium)
  • (cilastatin sodium + imipenem + relebactam)
  • (Pseudomonas + ventilator associated pneumonia) vaccine
  • AA-139
  • Aerucin
  • arbekacin
  • eravacycline
  • fosfomycin tromethamine
  • iclaprim mesylate
  • lefamulin acetate
  • MEDI-4893
  • Nu-2
  • Panaecin
  • panobacumab
  • plazomicin sulfate
  • Qn-2251
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

开发中产品的最新趋势

暂停中的计划

开发中止的产品

产品开发的里程碑

  • 关注资讯和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11079IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 4, 8, 8, 1 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Ventilator Associated Pneumonia (VAP) - Overview
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
  • Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
  • Ventilator Associated Pneumonia (VAP) - Drug Profiles
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products
  • Ventilator Associated Pneumonia (VAP) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by CytaCoat AB, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Evaxion Biotech ApS, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics Plc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor AG, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Spero Therapeutics Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2019
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top